Cutaneous T-cell lymphomas are rare non-Hodgkin lymphomas with substantial morbidity and mortality in advanced disease stages. We compared the efficacy of mogamulizumab, a novel monoclonal antibody directed against C-C chemokine receptor 4, with vorinostat in patients with previously treated cutaneous T-cell lymphoma.

Kim, Y.H., Bagot, M., Pinter-Brown, L., Rook, A.H., Porcu, P., Horwitz, S.M., et al. (2018). Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. THE LANCET ONCOLOGY, 19(9), 1192-1204 [10.1016/S1470-2045(18)30379-6].

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

Zinzani, Pier Luigi;
2018

Abstract

Cutaneous T-cell lymphomas are rare non-Hodgkin lymphomas with substantial morbidity and mortality in advanced disease stages. We compared the efficacy of mogamulizumab, a novel monoclonal antibody directed against C-C chemokine receptor 4, with vorinostat in patients with previously treated cutaneous T-cell lymphoma.
2018
Kim, Y.H., Bagot, M., Pinter-Brown, L., Rook, A.H., Porcu, P., Horwitz, S.M., et al. (2018). Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. THE LANCET ONCOLOGY, 19(9), 1192-1204 [10.1016/S1470-2045(18)30379-6].
Kim, Youn H; Bagot, Martine; Pinter-Brown, Lauren; Rook, Alain H; Porcu, Pierluigi; Horwitz, Steven M; Whittaker, Sean; Tokura, Yoshiki; Vermeer, Maar...espandi
File in questo prodotto:
Eventuali allegati, non sono esposti

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/674871
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 190
  • Scopus 427
  • ???jsp.display-item.citation.isi??? 393
social impact